MENU
Details
Group
Alternative Funds
Category
Trading
Net Assets
N/A
Fund Existence
N/A
Turnover
N/A
Capitalization
N/A
Yield
N/A
Total Expense Ratio
N/A
Investment Style
N/A
Risk (Beta)
N/A
Fundamentals
EDGE
Net Assets
N/A
Yield
N/A
Fund Existence
N/A
Total Expense Ratio
N/A
Turnover
N/A
Investment Style
N/A
Capitalization
N/A
Risk (Beta)
N/A
Manager Tenure
N/A
Administrative Fee
N/A
Annual Report Gross Expense Ratio
N/A
Assets in Top Ten Holdings
N/A
Average Credit Quality
N/A
Average Effective Duration
N/A
Average Effective Maturity
N/A
Fund of Funds
N/A
Fund Share Class Net Assets
N/A
Fund Type
N/A
Index Fund
N/A
Management Fee
N/A
Modified Duration
N/A
No Load Fund
N/A
Number of Long Holdings
N/A
Number of Net Holdings
N/A
Number of Short Holdings
N/A
Prospectus Acquired Expense Ratio
N/A
Weighting Top Ten Holdings
N/A
Gain YTD
N/A
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of linical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Category Trading
Profile
Fundamentals
Details